Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : to Invest More Than $100 Million to Research, Develop Antimalarials

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2018 | 07:52am CEST

By Pietro Lombardi

Novartis AG (NOVN.EB) said Tuesday that it will invest more than $100 million in the next five years in the research and development of the next-generation antimalarials.

The investment will focus on treatments to tackle resistance to antimalarials currently in use.

"Resistance to treatment presents the biggest threat to the incredible progress that has been made in the fight against malaria in the past 20 years. We cannot afford to wait; this is why we are committing to advance the research and development of next-generation treatments," said Chief Executive Vas Narasimhan.

The company's also said it will work to expand access to pediatric antimalarials and will help implement programs to reinforce health-care systems in four sub-Saharan countries.

Write to Pietro Lombardi at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
04:47pGenerics group Alvogen puts Eastern European operations up for sale - sources
RE
10:50aNOVARTIS : renews commitment to malaria elimination, investing USD 100 million t..
AQ
10:49aAVEXIS : Novartis tender offer for AveXis commences
AQ
10:49aAMGEN : Novartis presents first-of-its-kind evidence at AAN reinforcing robust a..
AQ
10:24aNOVARTIS : Jay Bradner bemoans `redundant investment in the biotech sector` for ..
AQ
09:39aNOVARTIS : Surface slips in first trading day
AQ
07:16aNOVARTIS : New Novartis analyses at AAN show siponimod's efficacy on disability ..
GL
04/19NOVARTIS : Patent Issued for Brake System (USPTO 9939603)
AQ
04/19NOVARTIS : Patent Issued for Adjusting Laser Treatment in Response to Changes in..
AQ
04/19NOVARTIS : Sandoz signs agreement with Pear Therapeutics to develop and commerci..
AQ
More news
News from SeekingAlpha
08:42aWALL STREET BREAKFAST, APRIL 20TH : Tough Trade Talk With China And Canada, Russ.. 
08:00aYOUR DAILY PHARMA SCOOP : Adamas Update, Shire Bidding War, Novartis Results 
07:03aWALL STREET BREAKFAST : Spring Meetings For IMF, World Bank 
04/19Novartis AG (NVS) Q1 2018 Results - Earnings Call Transcript 
04/19Novartis AG 2018 Q1 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 52 423 M
EBIT 2018 12 838 M
Net income 2018 8 826 M
Debt 2018 14 696 M
Yield 2018 3,76%
P/E ratio 2018 16,54
P/E ratio 2019 19,35
EV / Sales 2018 4,35x
EV / Sales 2019 4,18x
Capitalization 213 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 93,0 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
Srikant Madhav Datar Independent Non-Executive Director
Andreas von Planta Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-6.21%213 465
JOHNSON & JOHNSON-8.59%342 627
PFIZER0.30%217 064
ROCHE HOLDING LTD.-12.17%193 713
MERCK AND COMPANY4.21%158 813
AMGEN0.70%117 021